Brief: Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
23/09/2025 12:04
Sept 23 (Reuters) - Seres Therapeutics Inc MCRB.O: SERES THERAPEUTICS ANNOUNCES FURTHER CONSTRUCTIVE FEEDBACK FROM FDA ON SER-155 PHASE 2 STUDY PROTOCOL AND IMPLEMENTS COST REDUCTION ACTIONS TO EXTEND CASH RUNWAY SERES THERAPEUTICS INC - REDUCES WORKFORCE BY 25% TO EXTEND CASH RUNWAY SERES THERAPEUTICS INC - WORKFORCE REDUCTION TO RESULT IN $1.0-$1.4 MILLION SEVERANCE COSTS SERES THERAPEUTICS INC - SEEKS CAPITAL TO ADVANCE SER-155 PHASE 2 STUDY SERES THERAPEUTICS INC: EXPECTS TO EXTEND CASH RUNWAY WELL INTO Q2 2026 Source text: ID:nGNX7HlVNX Further company coverage: MCRB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seres Therapeutics
See all newsChinese automakers make tech-led pitch for Europe's premium car market
Brief: Seres Therapeutics - May Offer Up To $300 Million Of Securities
Seres Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Seres Therapeutics Q2 net income turns positive on VOWST sale gain
Brief: Seres Therapeutics Q2 EPS USD 0.47